These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 26970137)

  • 1. The National Cancer Institute's PREVENT Cancer Preclinical Drug Development Program: overview, current projects, animal models, agent development strategies, and molecular targets.
    Shoemaker RH; Suen CS; Holmes CA; Fay JR; Steele VE
    Semin Oncol; 2016 Feb; 43(1):189-197. PubMed ID: 26970137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early-phase development of cancer prevention agents: challenges and opportunities.
    Perloff M; Steele VE
    Cancer Prev Res (Phila); 2013 May; 6(5):379-83. PubMed ID: 23466485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.
    Lieberman R; Nelson WG; Sakr WA; Meyskens FL; Klein EA; Wilding G; Partin AW; Lee JJ; Lippman SM
    Urology; 2001 Apr; 57(4 Suppl 1):4-27. PubMed ID: 11295590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NCI Cancer Imaging Program efforts and their application to non-conventional radionuclides.
    Croft BY
    Q J Nucl Med Mol Imaging; 2008 Jun; 52(2):107-10. PubMed ID: 18043543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The chemopreventive agent development research program in the Division of Cancer Prevention of the US National Cancer Institute: an overview.
    Crowell JA
    Eur J Cancer; 2005 Sep; 41(13):1889-910. PubMed ID: 16005206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NCI Resources for Cancer Immunoprevention Research.
    Sei S; Srivastava S; Kelly HR; Miller MS; Leitner WW; Shoemaker RH; Szabo E; Castle PE
    Cancer Immunol Res; 2024 Apr; 12(4):387-392. PubMed ID: 38562082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The National Cancer Institute Experimental Therapeutics program.
    Doroshow JH
    Clin Adv Hematol Oncol; 2010 Jun; 8(6):403-4. PubMed ID: 20733549
    [No Abstract]   [Full Text] [Related]  

  • 8. Cancer chemoprevention and cancer preventive vaccines--a call to action: leaders of diverse stakeholder groups present strategies for overcoming multiple barriers to meet an urgent need.
    Herberman RB; Pearce HL; Lippman SM; Pyenson BS; Alberts DS
    Cancer Res; 2006 Dec; 66(24):11540-9. PubMed ID: 17158189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
    Greenwald P
    J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview of U.S. National Cancer Institute (USNCI) chemoprevention research.
    Johnson KA; Ford LG; Kramer B; Greenwald P
    Acta Oncol; 1994; 33(1):5-11. PubMed ID: 8142125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer chemoprevention agent development: the National Cancer Institute, Division of Cancer Prevention portfolio.
    Parnes HL; House MG; Kagan J; Kausal DJ; Lieberman R
    J Urol; 2004 Feb; 171(2 Pt 2):S68-74; discussion S75. PubMed ID: 14713758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Workshop on Immunomodulatory Agents: Report.
    Mohammed A; Dashwood RH; Dickinson S; Disis ML; Jaffee EM; Johnson BD; Khleif SN; Pollak MN; Schlom J; Shoemaker RH; Stanton SE; Wondrak GT; You M; Zhu H; Miller MS
    J Cancer Prev; 2021 Dec; 26(4):309-317. PubMed ID: 35047458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investor initiatives program: Public-private partnerships to expedite commercialization for NCI-funded small business entrepreneurs.
    Connors B; Lou XJ; Subedee A; Zhang K; Weingarten M; Narayanan D
    Clin Transl Sci; 2021 Nov; 14(6):2124-2131. PubMed ID: 34387931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer prevention: strategies for agent development.
    Parnes HL; House MG; Tangrea JA
    Curr Opin Oncol; 2013 May; 25(3):242-51. PubMed ID: 23518594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect on drug development of the National Cancer Institute's Cancer Therapy Evaluation Program.
    Zwiebel J
    Clin Adv Hematol Oncol; 2016 Mar; 14(3):157-9. PubMed ID: 27058027
    [No Abstract]   [Full Text] [Related]  

  • 16. NIMH initiatives to facilitate collaborations among industry, academia, and government for the discovery and clinical testing of novel models and drugs for psychiatric disorders.
    Brady LS; Winsky L; Goodman W; Oliveri ME; Stover E
    Neuropsychopharmacology; 2009 Jan; 34(1):229-43. PubMed ID: 18800066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NCI Cancer Imaging Program update.
    Croft BY
    J Nucl Med; 2008 Jun; 49(6):40N-42N. PubMed ID: 18511822
    [No Abstract]   [Full Text] [Related]  

  • 18. The National Cancer Institute's Cancer Prevention Research Program.
    DeWys WD; Costlow RD; Malone WF
    J Occup Med; 1986 Oct; 28(10):902-5. PubMed ID: 3772546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.
    Lawrence YR; Vikram B; Dignam JJ; Chakravarti A; Machtay M; Freidlin B; Takebe N; Curran WJ; Bentzen SM; Okunieff P; Coleman CN; Dicker AP
    J Natl Cancer Inst; 2013 Jan; 105(1):11-24. PubMed ID: 23231975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NIH and NCI support for development of novel therapeutics in gynecologic cancer: a user's guide.
    Minig L; Trimble EL; Birrer MJ; Kim KY; Takebe N; Abrams JS
    Gynecol Oncol; 2010 Feb; 116(2):177-80. PubMed ID: 19889449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.